Skip to main content
Premium Trial:

Request an Annual Quote

Tech Transfer to the People

"Clickstart a revolution," reads the homepage of Marblar, a new technology transfer-focused online community that aims to connect scientists' discoveries to investors and funds. At Wired's Social Dimenson blog, the Ewing Marion Kauffman Foundation's Samuel Arbesman, who advises Marblar, says that "while there are many startups that catalyze science… Marblar aims to catalyze the process of finding commercial uses for innovation." Arbesman adds that "Marblar acts like a reverse Innocentive [a crowdsourcing-based, problem-solving online community]. Where Innocentive sets scientific and technical challenges and rewards the best of the crowd-sourced solutions, Marblar starts with solutions — the technologies — and rewards those who can find the problems these technologies can solve."

Marblar is soliciting early-access participants at its website. "You might be a current scientist, a recovering scientist, or just a creative mind. Science is great, but the path to move scientific discoveries forward isn't always obvious, and it's harder still when only a couple of people are involved in that conversation," the company says. "That's why we built Marblar — to connect dormant ideas with brilliant people."

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.